The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 401–500 of 1,010
Johnsrud, A. J., Craig, J. K., Baird, J. H., Spiegel, J. Y., Muffly, L. S., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004716 · Cited by 87
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
Kühnl, A., Roddie, C., Kirkwood, A. A., Menne, T., Cuadrado, M. D. M., Marzolini, M. A. V., Osborne, W., Sanderson, R., O'Reilly, M. A., Townsend, W. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005807 · Cited by 81
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Bachanová, V., Bishop, M. R., Dahi, P. B., Dholaria, B., Grupp, S. A., Hayes‐Lattin, B., Janakiram, M., Maziarz, R. T., McGuirk, J. P., Nastoupil, L. J., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.008 · Cited by 78
Self-citationCD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function
Boucher, J. C., Li, G., Kotani, H., Cabral, M. L., Morrissey, D., Lee, S. B., Spitler, K., Beatty, N. J., Cervantes, E. V., Shrestha, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0253 · Cited by 82
Weiss, A. M., Lopez, M. A., Rawe, B. W., Manna, S., Chen, Q., Mulder, E. J., Rowan, S. J., & Esser-Kahn, A. P. (2023) · Macromolecules · doi:10.1021/acs.macromol.3c01223 · Cited by 89
Byrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
Tu, S., Zhou, X., Guo, Z., Huang, R., Yue, C., He, Y., Li, M., Chen, Y., Liu, Y., Chang, L., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01350 · Cited by 80
Sang, W., Shi, M., Yang, J., Cao, J., Xu, L., Yan, D., Yao, M., Liu, H., Li, W., Zhang, B., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3259 · Cited by 83
You, L., Han, Q., Zhu, L., Zhu, Y., Bao, C., Yang, C., Lei, W., & Qian, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01787 · Cited by 79
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy
Isser, A., Livingston, N. K., & Schneck, J. P. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120584 · Cited by 77
Baird, J. H., Frank, M. J., Craig, J. K., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., et al. (2020) · Blood · doi:10.1182/blood.2020009432 · Cited by 79
Riedell, P. A., Hwang, W., Nastoupil, L. J., Pennisi, M., McGuirk, J. P., Maziarz, R. T., Bachanová, V., Oluwole, O. O., Brower, J., Flores, O. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.011 · Cited by 79
Self-citationThe clinical potential of gene editing as a tool to engineer cell‐based therapeutics
Ashmore‐Harris, C., & Fruhwirth, G. O. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0268-z · Cited by 79
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 84
Kampouri, E., Walti, C. S., Gauthier, J., & Hill, J. A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2063833 · Cited by 84
Jiang, C., Hao, D., Jain, P., Li, Y., Cai, Q., Yao, Y., Nie, L., Liu, Y., Jin, J., Wang, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01655-0 · Cited by 80
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vučinić, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 81
Alcantara, M., Houillier, C., Blonski, M., Rubio, M., Willems, L., Rascalou, A. W., Garff‐Tavernier, M. L., Maloum, K., Bravetti, C., Souchet, L., et al. (2021) · Blood · doi:10.1182/blood.2021012932 · Cited by 77
Cardiotoxicity of T-Cell Antineoplastic Therapies
Ganatra, S., Dani, S. S., Yang, E. H., Zaha, V. G., & Nohria, A. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.07.014 · Cited by 78
Promises and challenges of a decentralized CAR T-cell manufacturing model
Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1238535 · Cited by 77
Korell, F., Laier, S., Sauer, S., Veelken, K., Hennemann, H., Schubert, M., Sauer, T., Pavel, P., Müller‐Tidow, C., Dreger, P., et al. (2020) · Cells · doi:10.3390/cells9051225 · Cited by 76
Targeting loss of heterozygosity for cancer-specific immunotherapy
Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 80
Systematic Review of Available CAR-T Cell Trials around the World
Barros, L. R. C., Couto, S. C. F., Santurio, D. S., Paixão, E. A., Cardoso, F. C., da Silva, V. J., Klinger, P. H. D. S., Ribeiro, P. D. A. C., Rós, F. A., de Oliveira, T. G. M., et al. (2022) · Cancers · doi:10.3390/cancers14112667 · Cited by 79
Wang, Y., Tong, C., Lu, Y., Wu, Z., Guo, Y., Liu, Y., Wei, J., Wang, C., Yang, Q., & Han, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01659-2 · Cited by 81
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00746-3 · Cited by 77
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
Wermke, M., Araujo, D. M., Chatterjee, M., Tsimberidou, A. M., Holderried, T. A. W., Jazaeri, A. A., Reshef, R., Bokemeyer, C., Alsdorf, W., Wetzko, K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03650-6 · Cited by 73
“However, IMA203 responders were more likely to have a lower tumor burden, which fits well with other data suggesting similar associations in lymphoma 26 and sarcoma 43 treated with CAR and TCR T cells, respectively.”
Imber, B. S., Sadelain, M., DeSelm, C. J., Batlevi, C. L., Brentjens, R. J., Dahi, P. B., Giralt, S., Park, J. H., Sauter, C. S., Scordo, M., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16541 · Cited by 76
Khaddour, K., Johanns, T. M., & Ansstas, G. (2020) · Pharmaceuticals · doi:10.3390/ph13110389 · Cited by 78
Falini, B., Martino, G., & Lazzi, S. (2022) · Leukemia · doi:10.1038/s41375-022-01764-1 · Cited by 85
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 84
Abbott, R. C., Cross, R. S., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020515 · Cited by 76
Krishnamoorthy, S., Ghobadi, A., Santos, R. D., Schilling, J. D., Malone, A. F., Murad, H., Bartlett, N. L., & Alhamad, T. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16367 · Cited by 75
Iams, W. T., Shiuan, E. F., Meador, C. B., Roth, M., Bordeaux, J., Vaupel, C., Boyd, K. L., Summit, I. B., Wang, L. L., Schneider, J. T., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.042 · Cited by 74
Schuster, S. J., Maziarz, R. T., Rusch, E. S., Li, J., Signorovitch, J., Romanov, V. V., Locke, F. L., & Maloney, D. G. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001304 · Cited by 76
Self-citationRoddie, C., Lekakis, L. J., Marzolini, M. A. V., Ramakrishnan, A., Zhang, Y., Hu, Y., Peddareddigari, V. G. R., Khokhar, N. Z., Chen, R. W., Basilico, S., et al. (2023) · Blood · doi:10.1182/blood.2022018598 · Cited by 78
Rovatti, P. E., Gambacorta, V., Lorentino, F., Ciceri, F., & Vago, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00147 · Cited by 74
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
Kittai, A. S., Bond, D. A., William, B. M., Saad, A. A., Penza, S. L., Efebera, Y. A., Larkin, K. T. M., Wall, S. A., Choe, H. K., Bhatnagar, B., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002783 · Cited by 73
Self-citationBeyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Shalabi, H., Gust, J., Taraseviciute, A., Wolters, P. L., Leahy, A. B., Sandi, C., Laetsch, T. W., Wiener, L. S., Gardner, R. A., Nussenblatt, V. R., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00456-y · Cited by 74
Sesques, P., Tordo, J., Ferrant, E., Safar, V., Wallet, F., Dhomps, A., Brisou, G., Bouafia, F., Karlin, L., Ghergus, D., et al. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003756 · Cited by 73
Self-citationIacoboni, G., Simó, M., Villacampa, G. J., Catalá, E., Carpio, C. D. C., Díaz‐Lagares, C., Vidal‐Jordana, Á., Bobillo, S., Marín‐Niebla, A., González, A. P., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04560-6 · Cited by 73
Liévin, R., Blasi, R. D., Morin, F., Galli, E., Allain, V., de Jorna, R., Vercellino, L., Parquet, N., Mebarki, M., Larghero, J., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01526-0 · Cited by 73
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 76
Monfrini, C., Stella, F., Aragona, V., Magni, M., Ljevar, S., Vella, C., Fardella, E., Chiappella, A., Nanetti, F., Pennisi, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0164 · Cited by 75
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 75
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 78
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
Agliardi, G., Dias, J., Rampotas, A., Garcia, J., & Roddie, C. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00273-4 · Cited by 79
Luo, H., Wang, N., Huang, L., Zhou, X., Jin, J., Li, C., Wang, D., Xu, B., Xu, J., Jiang, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0767-x · Cited by 74
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
Self-citationImproving CAR T cell therapy by optimizing critical quality attributes
Reddy, O. L., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.005 · Cited by 74
Emerging Immunotherapy for Acute Myeloid Leukemia
Tabata, R., Chi, S., Yuda, J., & Minami, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041944 · Cited by 74
Heart Failure With Targeted Cancer Therapies
Hahn, V. S., Zhang, K. W., Sun, L., Narayan, V., Lenihan, D. J., & Ky, B. (2021) · Circulation Research · doi:10.1161/circresaha.121.318223 · Cited by 73
Wei, G., Zhang, Y., Zhao, H., Wang, Y., Liu, Y., Liang, B., Wang, X., Xu, H., Cui, J., Wu, W., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0675 · Cited by 73
Application of CRISPR/Cas9 in Alzheimer’s Disease
Lu, L., Xi, Y., Cai, Y., Sun, M., & Yang, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.803894 · Cited by 79
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
Korell, F., Penack, O., Mattie, M., Schreck, N., Benner, A., Krzykalla, J., Wang, Z., Schmitt, M. W., Bullinger, L., Müller‐Tidow, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877477 · Cited by 72
Research Progress of Nanomedicine-Based Mild Photothermal Therapy in Tumor
He, X., Zhang, S., Tian, Y., Cheng, W., & Jing, H. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s405020 · Cited by 74
López, E., Karattil, R., Nannini, F., Cheung, G. W.-K., Denzler, L., Gálvez‐Cancino, F., Quezada, S. A., & Pulè, M. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006287 · Cited by 76
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 84
Expanding access to CAR T cell therapies through local manufacturing
Elsallab, M., & Maus, M. V. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01981-8 · Cited by 81
Cellular therapy: Immune‐related complications
Oved, J. H., Barrett, D. M., & Teachey, D. T. (2019) · Immunological Reviews · doi:10.1111/imr.12768 · Cited by 72
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 72
Passweg, J. R., Baldomero, H., Chabannon, C., Corbacioglu, S., de la Cámara, R., Dolstra, H., Glaß, B., Greco, R., Mohty, M., Neven, B., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01604-x · Cited by 71
Ram, R., Grisariu, S., Shargian, L., Amit, O., Bar-On, Y., Stepensky, P., Yeshurun, M., Avni, B. R., Hagin, D., Perry, C., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278288 · Cited by 71
CD58 loss in tumor cells confers functional impairment of CAR T cells
Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007891 · Cited by 77
Little, J. S., Aleissa, M. M., Beluch, K., Gonzalez-Bocco, I. H., Marty, F. M., Manne‐Goehler, J., Koo, S., Hammond, S. P., & Jacobson, C. A. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007474 · Cited by 74
Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 74
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 75
Graham, C., Lee, W., Wiggin, H. R., Supper, V. M., Leick, M. B., Birocchi, F., Yee, A. J., Petrichenko, A., Everett, J. K., Bushman, F. D., et al. (2023) · Blood · doi:10.1182/blood.2023021429 · Cited by 74
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70
Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
Feldmann, A., Hoffmann, A., Bergmann, R., Koristka, S., Berndt, N., Arndt, C., Loureiro, L. R., Kittel-Boselli, E., Mitwasi, N., Kegler, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1785608 · Cited by 73
Gudiol, C., Lewis, R. E., Strati, P., & Kontoyiannis, D. P. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30376-8 · Cited by 70
CAR T cells: Building on the CD19 paradigm
Levin, A. G., Rivière, I., Eshhar, Z., & Sadelain, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202049064 · Cited by 68
Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
Qasim, W. (2022) · Blood · doi:10.1182/blood.2022016204 · Cited by 70
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 76
CAR-T cell therapy for the treatment of adult high-grade gliomas
Park, S., Maus, M. V., & Choi, B. D. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00753-0 · Cited by 81
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 78
“T cell therapy is a new immunotherapy that provides a new therapeutic pathway for patients with refractory lymphoma, but ef fi cacy is mixed, with less than 40 percent achieving durable disease control 52,53 .”
CAR T-Cell Therapy for Large B-Cell Lymphoma — Who, When, and How?
Roschewski, M., Longo, D. L., & Wilson, W. H. (2022) · New England Journal of Medicine · doi:10.1056/nejme2118899 · Cited by 70
Song, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 68
Ramezankhani, R., Torabi, S., Minaei, N., Madani, H., Rezaeiani, S., Hassani, S., Gee, A. P., Dominici, M., Silva, D. N., Baharvand, H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.547653 · Cited by 72
Abramson, J. S., Irwin, K. E., Frigault, M. J., Dietrich, J., McGree, B. M., Jordan, J. T., Yee, A. J., Chen, Y., Raje, N. S., Barnes, J. A., et al. (2019) · Cancer · doi:10.1002/cncr.32411 · Cited by 69
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71
Combination therapy with oncolytic viruses and immune checkpoint inhibitors
Chiu, M. K.-L., Armstrong, E. J. L., Jennings, V., Foo, S., Crespo-Rodriguez, E., Bozhanova, G., Patin, E. C., McLaughlin, M., Mansfield, D., Baker, G., et al. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729351 · Cited by 71
Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity
Schmidts, A., Wehrli, M., & Maus, M. V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-061119-015600 · Cited by 69
Thapa, B., Caimi, P. F., Ardeshna, K. M., Solh, M., Carlo‐Stella, C., Kahl, B. S., & Hamadani, M. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002587 · Cited by 68
Guha, A., Addison, D., Jain, P., Gutierrez, J. M., Ghosh, A. K., Roddie, C., Lima, M. J. G. D., Al-Kindi, S. G., & Oliveira, G. H. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.036 · Cited by 69
Liang, Y., Liu, H., Lu, Z., Lei, W., Zhang, C., Li, P., Liang, A., Young, K. H., & Qian, W. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01044-y · Cited by 68
Lakomy, T., Akhoundova, D., Nilius, H., Kronig, M.-N., Novak, U., Daskalakis, M., Bacher, U., & Pabst, T. (2023) · Biomolecules · doi:10.3390/biom13020382 · Cited by 73
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan, A. N., Asija, S., Pendhari, J., & Purwar, R. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14076 · Cited by 72
Choquet, S., Soussain, C., Azar, N., Morel, V., Metz, C., Ursu, R., Waultier‐Rascalou, A., Blasi, R. D., Houot, R., Souchet, L., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27316 · Cited by 68
“16,18,19,37 In addition to systemic DLBCL, 16 the risk of relapse appears very low in patients who reach complete response at any time after CAR T-cell therapy.”
BackgroundBrexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Mian, A., & Hill, B. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1889510 · Cited by 68
CAR T-cell therapy for secondary CNS DLBCL
Ahmed, G., Hamadani, M., & Shah, N. N. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005292 · Cited by 67
Shao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 67
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
Heard, A. D., Landmann, J. H., Hansen, A. R., Papadopolou, A., Hsu, Y.-S., Selli, M. E., Warrington, J. M., Lattin, J., Chang, J., Ha, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31035-7 · Cited by 69
Rejeski, K., Burchert, A., Iacoboni, G., Sesques, P., Fransecky, L. R., Bücklein, V., Trenker, C., Hernani, R., Naumann, R., Schäfer, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007776 · Cited by 67
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 68
Self-citationHu, Y., Zu, C., Zhang, M., Wei, G., Li, W., Fu, S., Hong, R., Zhou, L., Wu, W., Cui, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102010 · Cited by 68
Crochet, G., Iacoboni, G., Couturier, A., Bachy, E., Iraola‐Truchuelo, J., Gastinne, T., Cartron, G., Fradon, T., Lesne, B., Kwon, M., et al. (2024) · Blood · doi:10.1182/blood.2024024526 · Cited by 68
Alexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 71
Wu, J., Meng, F., Cao, Y., Zhang, Y., Zhu, X., Wang, N., Wang, J., Huang, L., Zhou, J., & Xiao, Y. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00523-2 · Cited by 67
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
